(Q35569311)

8 August 2017

1 reference

title

Clinical applications of new therapeutic deliveries in migraine (English)

1 reference

8 August 2017

1 reference

Carl Dahlöf

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

8 August 2017

28 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14581656

full work available at URL

25 March 2024

https://www.neurology.org/doi/full/10.1212/WNL.61.8_suppl_4.S31

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

25 March 2024

1 reference

8 August 2017

volume

61

1 reference

8 August 2017

issue

8 Suppl 4

1 reference

8 August 2017

page(s)

S31-4

1 reference

Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Sumatriptan. An updated review of its use in migraine

25 March 2024

2

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Sumatriptan: pharmacological basis and clinical results

25 March 2024

3

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs

25 March 2024

4

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey

25 March 2024

6

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Integrating the triptans into clinical practice

25 March 2024

7

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Effect of migraine attacks on paracetamol absorption

25 March 2024

9

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid

25 March 2024

10

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Migraine and Drug Absorption

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

25 March 2024

14

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies

25 March 2024

15

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine

25 March 2024

16

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

25 March 2024

17

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers

25 March 2024

18

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Reproductive dysfunction in women with epilepsy

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial

25 March 2024

22

1 reference

https://api.crossref.org/works/10.1212/WNL.61.8_SUPPL_4.S31

25 March 2024

Identifiers

1 reference

8 August 2017

1 reference